Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,008 public trials 572 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT00656305

Conditions
Blood Protein Disorders, Bone Diseases, Bone Metastases, +42 more
Locations
  • University of California San Diego La Jolla, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • University MRI & Diagnostic Imaging Centers Boca Raton, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 14 locations
View Trial Details
Completed

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

NCT00068718

Conditions
Blast Crisis, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blood Protein Disorders, +38 more
Locations
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
  • Universitaet Leipzig Leipzig, Germany
  • University of Torino Torino, Italy
View Trial Details
Completed

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00096161

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +42 more
Locations
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
  • LDS Hospital Salt Lake City, Utah, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

NCT00789776

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +49 more
Locations
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
  • Children's Hospital of Wisconsin Milwaukee, Wisconsin, United States
  • Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Completed

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

NCT00040846

Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), +164 more
Locations
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
  • LDS Hospital Salt Lake City, Utah, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
View Trial Details
Completed

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

NCT00089011

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +250 more
Locations
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
  • LDS Hospital Salt Lake City, Utah, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Longterm Follow-up of Subjects Treated With bb2121

NCT02786511

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Stanford Cancer Center Palo Alto, California, United States
  • National Cancer Institute Bethesda, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
View Trial Details

Related conditions